Alpha Tau Submits To Japanese PMDA For Pre-Market Approval Of Alpha DaRT In Patients With Recurrent Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW) has submitted a pre-market approval request to Japan's PMDA for its Alpha DaRT therapy for recurrent head and neck cancer. The submission follows successful clinical trials in Japan that met safety and efficacy endpoints. Alpha Tau and HekaBio are in talks with biopharmaceutical companies for a commercial partnership in Japan. The therapy targets solid tumor cancers post-radiation treatment, with over 10,000 new cases annually in Japan.
November 20, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpha Tau Medical Ltd. has submitted for pre-market approval in Japan for its Alpha DaRT therapy, showing positive trial results for recurrent head and neck cancer.
The news of a successful submission for pre-market approval in Japan is a significant positive development for Alpha Tau Medical. The successful clinical trial results and ongoing discussions for commercial partnerships in Japan suggest a strong potential for future revenue growth in a market with over 10,000 new cases of head and neck cancer annually. This could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100